Hanall Biopharma stock: Q3 net income rises 924.1% to KRW 3.1 billion

Published on 10/30/2026 at 01:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Hanall Biopharma stock is in focus after the company reported its third-quarter results. Revenue declined year on year, while operating income increased.

Hanall Biopharma reports quarterly results

The reported period covered July through September 2026.
Revenue declined year on year despite higher operating income.
The results were disclosed in a regulatory filing cited by Yonhap.

Hanall Biopharma, KR7009420001, Illustration mit AI erstellt.

Hanall Biopharma reported net income of KRW 3.1 billion for the third quarter on October 28, 2026, according to Yonhap News Agency. The July-to-September result was 924.1 percent higher than in the same period a year earlier.

Profit growth outpaced revenue trend

The company said operating income rose 265 percent year on year to KRW 1.3 billion. Revenue, however, fell 2.2 percent to KRW 39.9 billion, showing that the earnings improvement came despite lower reported sales.

For investors, the quarterly figures provide a current view of profitability and sales momentum, but they do not by themselves establish a lasting change in the company's earnings trajectory. The result should therefore be assessed alongside future filings and developments in Hanall Biopharma's pharmaceutical portfolio.